Antiviral Technologies LLC
Tranexamic Technologies is dedicated to developing transformative therapies based on Tranexamic Acid (TA) and its derivatives. The company focuses on innovative solutions for various medical challenges, including antiviral treatments, cancer therapies, and anti-aging applications. With a strong emphasis on research and collaboration, Tranexamic Technologies aims to enhance health outcomes through groundbreaking medical advancements.
Industries
N/A
Products
Synthetic positively charged amino acid analog therapeutics (development candidates)
Small-molecule analogs and mimetics designed to antagonize positively charged amino acids (lysine/arginine/histidine) to modulate protein–protein interactions for antiviral, anticancer, and aging-related indications.
Nasal spray candidate for respiratory virus prophylaxis and early treatment
Intranasal formulation intended for early-symptom administration and episodic prophylaxis against respiratory viruses; development pathway includes challenge studies and population trials.
Topical gel candidate for dermatologic and HSV treatment
Gel-based topical formulation developed for reduction of bruising/inflammation in aesthetic use and for topical treatment of HSV lesions and certain skin cancers.
Synthetic positively charged amino acid analog therapeutics (development candidates)
Small-molecule analogs and mimetics designed to antagonize positively charged amino acids (lysine/arginine/histidine) to modulate protein–protein interactions for antiviral, anticancer, and aging-related indications.
Nasal spray candidate for respiratory virus prophylaxis and early treatment
Intranasal formulation intended for early-symptom administration and episodic prophylaxis against respiratory viruses; development pathway includes challenge studies and population trials.
Topical gel candidate for dermatologic and HSV treatment
Gel-based topical formulation developed for reduction of bruising/inflammation in aesthetic use and for topical treatment of HSV lesions and certain skin cancers.
Services
Preclinical efficacy and IND-enabling study design
Design and execution support for in vitro and in vivo efficacy studies and planning of IND-enabling nonclinical studies, including toxicology and PK considerations.
Formulation development for nasal and topical delivery
Development of nasal spray and gel-based topical formulations with feasibility and PK guidance for respiratory and dermatologic applications.
IP licensing and partnership development
Licensing of method/composition patents, strategic partnerships for development and commercialization, and support for combination therapy IP strategies.
Clinical program design and biomarker strategies
Design of clinical challenge studies, population trials, and biomarker tracking protocols for indications including respiratory viruses and concussion.
Preclinical efficacy and IND-enabling study design
Design and execution support for in vitro and in vivo efficacy studies and planning of IND-enabling nonclinical studies, including toxicology and PK considerations.
Formulation development for nasal and topical delivery
Development of nasal spray and gel-based topical formulations with feasibility and PK guidance for respiratory and dermatologic applications.
IP licensing and partnership development
Licensing of method/composition patents, strategic partnerships for development and commercialization, and support for combination therapy IP strategies.
Clinical program design and biomarker strategies
Design of clinical challenge studies, population trials, and biomarker tracking protocols for indications including respiratory viruses and concussion.
Expertise Areas
- Antiviral therapeutics development (host-directed)
- Topical and intranasal/respiratory drug delivery
- Oncology preclinical development
- Nonclinical pharmacology and toxicology
Key Technologies
- Nasal spray delivery for respiratory indication
- Gel-based topical formulation
- Fluorescence-based activity assays
- Surface plasmon resonance (SPR) assays